Hen egg lysozyme attenuates inflammation and modulates local gene expression in a porcine model of dextran sodium sulfate (DSS)-Induced Colitis

Journal of Agricultural and Food Chemistry

Volumn 57, Issue 6, 2009, Pages 2233-2240

  Lee, Maggie ^a   Kovacs Nolan, Jennifer ^a   Yang, Chengbo ^a   Archbold, Tania ^a   Fan, Ming Z ^a   Mine, Yoshinori ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Anti inflammatory; Colitis; Dextran sodium sulfate (DSS); Inflammatory bowel disease (IBD); Lysozyme

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; DEXTRAN SULFATE; HEN EGG LYSOZYME; LYSOZYME;

ANIMAL; ARTICLE; COLITIS; DIET THERAPY; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; SECRETION; SWINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INTESTINAL MUCOSA; MURAMIDASE; SWINE;

ANIMALIA; SUS;

EID: 64549148418     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf803133b     Document Type: Article

References (53)

1. Xavier, R. J.; Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448 (7152), 427-434.
2. Podolsky. D. K. The current future understanding of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 2002, 16, 933-43.
3. Fiocchi, C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115, 182-205.
4. Torres, M. I.; Rios, A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J. Gastroenterol. 2008, 14, 1972-1980.
5. Atreya, R.; Neurath, M. F. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol. 2008, 1, 175-182.
6. Losso, L. N.; Nakai, S.; Charter, E. A. Lysozyme. In Natural Food Animicrobial Systems; Naidu, A., Ed.; CRC Press: New-York, 2000; pp 185-210.
7. Chipman, D. M.; Sharon, N. Mechanism of lysozyme action. Science 1969, 165, 454-65.
8. Lin, K.-C.; Wey, M.-T.; Kan, L.-S.; Shiuan, D. Characterization of the interactions of lysozyme with DNA by surface plasmon resonance and circular dichroism spectroscopy. Appl. Biochem. Biotechnol. 2008, doi: 10.1007/sl2010-008-8348-3.
9. Nuding, S.; Fellermann, K.; Wehkamp, J.; Stange, E. F. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007, 56, 1240-1247.
10. Wehkamp, J.; Fellermann, K.; Stange, E. F. Human defensins in Crohn's disease. Chem. Immunol. Allergy 2005, 86, 42-54.
11. Liu, H.; Zheng, F.; Cao, Q.; Ren, B.; Zhu, L.; Striker, G.: Vlassara, H. Amelioration of oxidant stress by the defensin lysozyme. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E824-E832.
12. Hung, C. R.; Chen, W. H.; Wang, P. S. Protective effect of lysozyme chloride on gastric oxidative stress and hemorrhagic ulcers in severe atherosclerotic rats. Med. Sci. Monit. 2007, 13, BR271-BR279.
13. Wirtz, S.; Neufert, C.; Weigmann, B.; Neurath, M. F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2, 541-546.
14. Wirtz, S.; Neurath, M. F. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immuno-therapy of inflammatory bowel disease. Int. J. Colorectal Dis. 2000, 15, 144-160.
15. Dieleman, L. A.; Palmen, M. J.; Akol, H.; Bloemena, E.; Pena, A. S.; Meuwissen, S. G.; Van Rees, E. P. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 1998, 114, 385-391.
16. Bassaganya-Riera, J.; Hontecillas, R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin. Nutr. 2006, 25, 454-465.
17. Mackenzie, M. L.; Warren, M. R.; Wykes, L. J. Colitis increases albumin synthesis at the expense of muscle protein synthesis in macronutrient-restricted piglets. J. Nutr. 2003, 133, 1875-1881.
18. Miller, E. R.; Ullrey, D. E. The pig as a model for human nutrition. Annu. Rev. Nutr. 1987, 7, 361-382.
19. Merritt, A. M.; Buergelt, C. D.; Sanchez, L. C. Porcine ileitis model induced by TNBS-ethanol instillation. Dig. Dis. Sci. 2002, 47, 879-885.
20. Thymann, T.; Burrin, D. G.; Tappenden, K. A.; Bjornvad, C. R.; Jensen, S. K.; Sangild, P. T. Formula-feeding reduces lactose digestive capacity in neonatal pigs. Br. J. Nutr. 2006, 95, 1075-1081.
21. Graefe, H.; Gutschow, B.; Gehring, H.; Dibbelt, L. Sensitive and specific photometric determination of mannitol in human serum. Clin. Chem. Lab. Med. 2003, 41 (8), 1049-1055.
22. Lunn, P. G.; Northrop, C. A.; Northrop, A. J. Automated enzymatic assays for the determination of intestinal permeability probes in urine. 2. Mannitol. Clin. Chim. Acta 1989, 183, 163-170.
23. Rozen, S.; Skaletsky, H. J. Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols: Methods in Molecular Biology; Krawetz, S., Misener S., Eds.; Humana Press: Totowa, NJ, 2000; pp 365-386.
24. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001, 25, 402-408.
25. Harder, J.; Glaser, R.; Schroder, J. M. Human antimicrobial proteins effectors of innate immunity. J. Endotoxin. Res. 2007, 13, 317-338.
26. Klein, S.; Meyers, S.; O'Sullivan, P.; Barton, D.; Leleiko, N.; Janowitz, H. D. The metabolic impact of active ulcerative colitis. Energy expenditure and nitrogen balance. J. Clin. Gastroenterol. 1988, 10, 34-40.
27. McGuckin, M. A.; Eri, R.; Simms, L. A.; Florin, T. H.; Radford-Smith, G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 2008, 15, 100-113.
28. Al-Sadi, R.; Ye, D.; Dokladny, K.; Ma, T. Y. Mechanism of 1L-1β-induced increase in intestinal epithelial tight junction permeability. J. Immunol. 2008, 180, 5653-5661.
29. Wang, F.; Graham, W. V.; Wang, Y.; Witkowski, E. D.; Schwarz, B. T.; Turner, J. R. Interferon-gamma and tumor necrosis factor-a synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. 2005, 166, 409-419.
30. Kwon, K. H.; Murakami, A.; Tanaka, T.; Ohigashi, H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem. Pharmacol. 2005, 69, 395-406.
31. Blennerhassett, M. G.; Bovell, F. M.; Lourenssen, S.; McHugh, K. M. Characteristics of inflammation-induced hypertrophy of rat intestinal smooth muscle cell. Dig. Dis. Sci. 1999, 44, 1265-1272.
32. Graham, M. F.; Diegelmann, R. F.; Elson, C. O.; Lindblad, W. J.; Gotschalk, N.; Gay, S.; Gay, R. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988, 94, 257-265.
33. Tai, E. K.; Wu, W. K.; Wong, H. P.; Lam, E. K.; Yu, L.; Cho, C. H. A new role for cathelicidin in ulcerative colitis in mice. Exp. Biol Med. (Maywood) 2007, 232, 799-808.
34. Van der Sluis, M.; De Koning, B. A.; De Bruijn, A. C.; Velcich, A.; Meijerink, J. P.; Van Goudoever, J. B.; Buller, H. A.; Dekker, J.; Van Seuningen, I.; Renes, I. B.; Einerhand, A. W. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131, 117-129.
35. Daig, R.; Andus, T.; Aschenbrenner, E.; Falk, W.; Scholmerich, J.; Gross, V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996, 38, 216-222.
36. Egger, B.; Bajaj-Elliott, M.; MacDonald, T. T.; Inglin, R.: Eysselein, V. E.; Buchler, M. W. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000, 62, 240-248.
37. Atreya, R.; Neurath, M. F. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 2005, 28 (3), 187-196.
38. Plevy, S. E.; Landers, C. J.; Prehn, J.; Carramanzana, N. M.; Deem, R. L.: Shealy, D.; Targan, S. R. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 1997, 159, 6276-6282.
39. Noble, A.; Baldassano, R.; Mamula, P. Novel therapeutic options in the inflammatory bowel disease world. Dig. Liver Dis. 2008, 40, 22-31.
40. Nielsen, O. H.; Rudiger, N.; Gaustadnes, M.; Horn, T. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand. J. Gastroenterol. 1997, 32, 1028-1034.
41. Comalada, M.; Peppelenbosch, M. P. Impaired innate immunity in Crohn's disease. Trends Mol. Med. 2006, 12, 397-399.
42. Nielsen, O. H.; Koppen, T.; Rudiger, N.; Horn, T.; Eriksen, J.: Kirman. I. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig. Dis. Sci. 1996, 41, 1786-1793.
43. Bento, A. F.; Leite, D. F.; Claudino, R. F.; Hara, D. B.; Leal, P. C.; Calixto, J. B. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J. Leu-kocyte Biol. 2008, 84, 1213-1221.
44. Kucharzik, T.; Stoll, R.; Lugering, N.; Domschke, W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (1BD). Clin. Exp. Immunol. 1995, 100, 452-456.
45. Hausmann, M.; Obermeier, F.; Paper, D. H.; Balan, K.; Dunger, N.; Menzel, K.; Falk, W.; Schoelmerich, J.; Herfarth, H.: Rogler, G. In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clin. Exp. Immunol. 2007, 148, 373-381.
46. Mizoguchi, A.; Mizoguchi, E. Inflammatory bowel disease, past, present and future: lessons from animal models. J. Gastroenterol. 2008, 43, 1-17.
47. Kaiko, G. E.; Horvat, J. C.; Beagley, K. W.; Hansbro, P. M. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 2008, 123, 326-338.
48. Fantini, M. C.; Dominitzki, S.; Rizzo, A.; Neurath, M. F.; Becker, C. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat. Protoc. 2007, 2, 1789-1794.
49. Veldhoen, M.; Hocking, R. J.; Atkins, C. J.; Locksley, R. M.; Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24, 179-189.
50. Zhou, L.; Lopes, J. E.; Chong, M. M.; Ivanov, I. I.: Min, R.; Victora, G. D.; Shen, Y.; Du, J.; Rubtsov, Y. P.; Rudensky, A. Y.: Ziegler, S. F.; Littman, D. R. TGF-β-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453 236-240.
51. Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101, 455-458.
52. Brown, J. B.; Lee, G.; Grimm, G. R.; Barrett, T. A. Therapeutic benefit of pentostatin in severe IL-10-/-colitis. Inflamm. Bowel Dis. 2008, 14, 880-887.
53. Mine, Y.; Ma, F.; Lauriau, S. Antimicrobial peptides released by enzymatic hydrolysis of hen egg white lysozyme. J. Agric. Food Chem. 2004, 52, 1088-1094.